| SC 13G/A | 2024-02-14 | BIOTECHNOLOGY VALUE FUND L P | 4D Molecular Therapeutics, Inc. | 2,132,411 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | 4D Molecular Therapeutics, Inc. | 4,163,211 | 9.7% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners III, L.P. | 4D Molecular Therapeutics, Inc. | 4,400,000 | 8.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Deep Track Capital, LP | 4D Molecular Therapeutics, Inc. | 2,284,372 | 5.3% | EDGAR |
| SC 13G/A | 2024-02-14 | Kirn David | 4D Molecular Therapeutics, Inc. | 2,033,069 | 4.7% | EDGAR |
| SC 13G/A | 2024-02-13 | JANUS HENDERSON GROUP PLC | 4D Molecular Therapeutics, Inc. | 3,093,296 | 7.2% | EDGAR |
| SC 13G/A | 2024-01-25 | BlackRock Inc. | 4D Molecular Therapeutics, Inc. | 3,464,587 | 8.1% | EDGAR |
| SC 13G/A | 2024-01-08 | VIKING GLOBAL INVESTORS LP | 4D Molecular Therapeutics, Inc. | 4,787,914 | 11.2% | EDGAR |
| SC 13G/A | 2024-01-08 | VIKING GLOBAL INVESTORS LP | 4D Molecular Therapeutics, Inc. | 4,247,914 | 9.9% | EDGAR |
| SC 13G | 2023-06-05 | RA CAPITAL MANAGEMENT, L.P. | 4D Molecular Therapeutics, Inc. | 2,789,721 | 6.7% | EDGAR |
| SC 13G | 2023-05-15 | Venrock Healthcare Capital Partners III, L.P. | 4D Molecular Therapeutics, Inc. | 2,887,517 | 8.7% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | 4D Molecular Therapeutics, Inc. | 2,656,901 | 8.2% | EDGAR |
| SC 13G/A | 2023-02-09 | JANUS HENDERSON GROUP PLC | 4D Molecular Therapeutics, Inc. | 1,466,267 | 4.5% | EDGAR |
| SC 13G/A | 2023-02-08 | Kirn David | 4D Molecular Therapeutics, Inc. | 2,022,498 | 6.2% | EDGAR |
| SC 13G/A | 2023-01-31 | BlackRock Inc. | 4D Molecular Therapeutics, Inc. | 2,508,632 | 7.7% | EDGAR |
| SC 13G/A | 2022-06-21 | BIOTECHNOLOGY VALUE FUND L P | 4D Molecular Therapeutics, Inc. | 2,132,411 | 6.6% | EDGAR |
| SC 13G/A | 2022-02-14 | VIKING GLOBAL INVESTORS LP | 4D Molecular Therapeutics Inc. | 3,937,914 | 12.3% | EDGAR |
| SC 13G/A | 2022-02-14 | Deep Track Capital, LP | 4D Molecular Therapeutics Inc. | 1,900,000 | 5.9% | EDGAR |
| SC 13G/A | 2022-02-14 | SCHAFFER DAVID | 4D Molecular Therapeutics Inc. | 901,215 | 2.8% | EDGAR |
| SC 13G/A | 2022-02-14 | Kirn David | 4D Molecular Therapeutics Inc. | 2,034,375 | 6.3% | EDGAR |